NO20061402L - Anti-tumorformuleringer som omfatter defibrotid alene eller i kombinasjon med andre antitumormidler - Google Patents

Anti-tumorformuleringer som omfatter defibrotid alene eller i kombinasjon med andre antitumormidler

Info

Publication number
NO20061402L
NO20061402L NO20061402A NO20061402A NO20061402L NO 20061402 L NO20061402 L NO 20061402L NO 20061402 A NO20061402 A NO 20061402A NO 20061402 A NO20061402 A NO 20061402A NO 20061402 L NO20061402 L NO 20061402L
Authority
NO
Norway
Prior art keywords
combination
antitumor agents
formulations
defibrotide
alone
Prior art date
Application number
NO20061402A
Other languages
English (en)
Inventor
Massimo Iacobelli
Laura Iris Ferro
Paul Richardson
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa filed Critical Gentium Spa
Publication of NO20061402L publication Critical patent/NO20061402L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det er beskrevet anvendelse av defibrotid som et anti- tumormiddel, alene eller i kombinasjon med andre aktive ingredienser med anti-tumorvirkning.
NO20061402A 2003-09-05 2006-03-28 Anti-tumorformuleringer som omfatter defibrotid alene eller i kombinasjon med andre antitumormidler NO20061402L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001714A ITMI20031714A1 (it) 2003-09-05 2003-09-05 Formazioni ad azione antitumorale.
US53934404P 2004-01-28 2004-01-28
PCT/EP2004/009723 WO2005023273A1 (en) 2003-09-05 2004-08-27 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents

Publications (1)

Publication Number Publication Date
NO20061402L true NO20061402L (no) 2006-03-28

Family

ID=37064585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061402A NO20061402L (no) 2003-09-05 2006-03-28 Anti-tumorformuleringer som omfatter defibrotid alene eller i kombinasjon med andre antitumormidler

Country Status (23)

Country Link
US (2) US8551967B2 (no)
EP (1) EP1660100B1 (no)
JP (1) JP4671962B2 (no)
KR (1) KR20060061367A (no)
CN (1) CN100490820C (no)
AT (1) ATE399558T1 (no)
AU (1) AU2004269896B2 (no)
BR (1) BRPI0414114A (no)
CA (1) CA2537226C (no)
DE (1) DE602004014787D1 (no)
DK (1) DK1660100T3 (no)
ES (1) ES2308223T3 (no)
IL (1) IL173785A0 (no)
IS (1) IS8334A (no)
IT (1) ITMI20031714A1 (no)
MX (1) MXPA06002489A (no)
NO (1) NO20061402L (no)
PT (1) PT1660100E (no)
RS (1) RS20060154A (no)
RU (1) RU2348413C2 (no)
UA (1) UA83500C2 (no)
WO (1) WO2005023273A1 (no)
ZA (1) ZA200601852B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070121001A (ko) * 2005-03-03 2007-12-26 젠티엄 에스피에이 신혈관 형성-의존성 종양 치료용 약학적 제제
EP1872787A1 (en) * 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
KR102038357B1 (ko) 2012-06-22 2019-10-31 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
US10380734B2 (en) * 2017-02-27 2019-08-13 Aniket Bharat Parikh System, method and computer program product for security analysis of jewelry items
CN111132663A (zh) * 2017-08-03 2020-05-08 爵士制药爱尔兰有限公司 包含高浓度核酸的制剂
AU2019252790A1 (en) 2018-04-12 2020-10-15 Jazz Pharmaceuticals, Inc. Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
WO2021174039A1 (en) 2020-02-28 2021-09-02 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
DE9202745U1 (de) 1992-03-02 1992-04-30 Howmedica Gmbh, 2314 Schoenkirchen Vorrichtung zum Verspannen von Wirbeln der menschlichen Wirbelsäule
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
AU754242B2 (en) * 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
WO1998054313A2 (en) 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
CA2377385A1 (en) * 1999-06-03 2000-12-14 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
PL366223A1 (en) * 2000-12-29 2005-01-24 Bio-Technology General Corp. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
AU2002353783A1 (en) 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
CN1304011C (zh) * 2002-05-31 2007-03-14 雷根斯堡大学医学院 保护性寡聚脱氧核糖核苷酸的制药用途
AU2003263764A1 (en) * 2002-07-01 2004-01-19 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US20060293256A1 (en) 2002-08-06 2006-12-28 Masateru Yamada Remedy or preventive for kidney disease and method of diagnosing kidney disease
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
KR20070121001A (ko) 2005-03-03 2007-12-26 젠티엄 에스피에이 신혈관 형성-의존성 종양 치료용 약학적 제제
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases

Also Published As

Publication number Publication date
PT1660100E (pt) 2008-10-14
AU2004269896A1 (en) 2005-03-17
US20060211646A1 (en) 2006-09-21
AU2004269896B2 (en) 2009-11-19
US20140005256A1 (en) 2014-01-02
KR20060061367A (ko) 2006-06-07
CA2537226A1 (en) 2005-03-17
CN100490820C (zh) 2009-05-27
EP1660100A1 (en) 2006-05-31
ATE399558T1 (de) 2008-07-15
MXPA06002489A (es) 2006-06-20
RU2348413C2 (ru) 2009-03-10
IS8334A (is) 2006-02-28
ES2308223T3 (es) 2008-12-01
ZA200601852B (en) 2007-06-27
WO2005023273A1 (en) 2005-03-17
CN1845746A (zh) 2006-10-11
JP4671962B2 (ja) 2011-04-20
JP2007504194A (ja) 2007-03-01
BRPI0414114A (pt) 2006-10-31
RU2006109210A (ru) 2007-10-10
EP1660100B1 (en) 2008-07-02
IL173785A0 (en) 2006-07-05
ITMI20031714A1 (it) 2005-03-06
UA83500C2 (uk) 2008-07-25
US8551967B2 (en) 2013-10-08
DK1660100T3 (da) 2008-11-10
RS20060154A (sr) 2008-08-07
CA2537226C (en) 2016-05-03
DE602004014787D1 (de) 2008-08-14

Similar Documents

Publication Publication Date Title
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell&#39;epidermide
AR050616A1 (es) Composiciones farmaceuticas para el tratamiento de trastornos hiperproliferativos.
IL211084A0 (en) Single use module
IL186104A0 (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
PT1411908E (pt) Tratamento de infeccoes da unha com no
ITMI20052171A1 (it) Composti e-amminocarbonil bicicloepten pirimidindiamminici stereoisomericamente arricchiti e loro uso
DK1660100T3 (da) Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler
EP1453525A4 (en) SELECTIVE TARGETING OF APOPTOTIC CELLS
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita&#39; antiossidante.
DE60036437D1 (de) Avermectinen oder Milbemycine und bis-Aryl-Derivate enthaltende Anthelminthische Zusammensetzungen
NL1026201A1 (nl) Heterodyne bundelafgifte met actieve sturing van twee orthogonale polarisaties.
DK1608344T3 (da) Orale cladribin-formuleringer
DE50310323D1 (de) Wässrige polyurethanzubereitungen
WO2005000204A3 (en) Pancreatic cancer treatment
PA8506201A1 (es) Quimioterapia de combinacion (combination chemotherapy)
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
NO20065791L (no) Asyklovir-formuleringer
NO20052954D0 (no) Diterpenoidforbindelser, sammensetninger derav og deres anvendelse som anti-cancer eller anti-fungale midler
BRPI0417513A (pt) agentes combinados de chp-gemcitabina e seu uso como substáncias antitumorais ativas
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
ES2068469T3 (es) Agente para la proteccion de plantas contra el ataque por microorganismos.
WO2005039484A3 (en) Indolocarbazole anticancer agents and methods of using same
AU4344202A (en) Indolocarbazole anticancer agents and methods of using them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application